Ventripoint Announces Non-Brokered Convertible Debenture Units Private Placement and Share Issuance

About this update from Ventripoint Diagnostics Ltd.

Ventripoint Announces Non-Brokered Convertible Debenture Units Private Placement and Share Issuance (TheNewswire) Toronto, Ontario – TheNewswire - August 26, 2025 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ” ) , ( TSXV:VPT) announces a non-brokered private placement of up to CDN$500,000 (the “ Offering ”) of unsecured convertible debenture units (“ Units ”) subject to TSXV Venture Exchange (the “ Exchange ”) acceptance. Each Unit will be comprised of one (1) unsecured convertible debenture principal amount of $1,000 (“ Debentures ”) convertible into common shares (“ Common Shares ”) of the Corporation, and 9,000 common share purchase warrants (“ Warrants ”). Depending on market conditions, the Corporation may increase the size of the Offering, subject to approval of the Exchange. The Debentures will be convertible into Common Shares of the Corporation at the option of the holder at any time prior to maturity at a conversion price of $0.11 per Common Share (the “ Conversion Price ”). E ach whole Warrant will entitle the holder thereof to purchase one (1) Common Share at a price of $0.14 until December 31, 2027. The Debentures will mature December 31, 2027 and will bear interest at ten per cent (10%) payable semi-annually in arrears in either cash or at the option of the Corporation by issuance of Common Shares at a 20-day VWAP market price, determined at time of payment, subject to Exchange approval. The Corporation may pay cash finder’s fee and issue common share purchase warrants (“ Finder’s Warrants ”) of up to 4% of the gross proceeds of the Offering. Each Finder’s Warrant will be exercisable into one Common Share at an exercise price of CDN$0.11 per Common Share for a period of 18 months. The Corporation will use the proceeds of the Offering to fund operational costs related sales and marketing, additional key personnel, and general working capital purposes. All securities issued and issuable pursuant to the Offering will be subject to a hold period of four months plus one day from the date of closing of the Offering. The Offering is subject to approval by the Exchange. The securities offered will not be registered under the U.S. Securities Act of 1933, ...

View stock analysis, news, and events for Ventripoint Diagnostics Ltd.